ImmunityBio, Inc. (IBRX)
7.45
+0.62
(+9.08%)
USD |
NASDAQ |
Jul 30, 16:00
7.46
+0.01
(+0.13%)
Pre-Market: 08:41
ImmunityBio EPS Diluted (Quarterly) : -0.6162 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.6162 |
| December 31, 2025 | -0.0626 |
| September 30, 2025 | -0.071 |
| June 30, 2025 | -0.1042 |
| March 31, 2025 | -0.152 |
| December 31, 2024 | -0.0933 |
| September 30, 2024 | -0.1436 |
| June 30, 2024 | -0.1959 |
| March 31, 2024 | -0.1993 |
| December 31, 2023 | -0.3479 |
| September 30, 2023 | -0.1918 |
| June 30, 2023 | -0.3152 |
| March 31, 2023 | -0.2716 |
| December 31, 2022 | -0.2682 |
| September 30, 2022 | -0.2773 |
| June 30, 2022 | -0.2377 |
| March 31, 2022 | -0.2584 |
| December 31, 2021 | -0.2294 |
| September 30, 2021 | -0.2236 |
| June 30, 2021 | -0.2294 |
| March 31, 2021 | -0.208 |
| December 31, 2020 | -0.2955 |
| September 30, 2020 | -0.2012 |
| June 30, 2020 | -0.2034 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1867 |
| December 31, 2019 | -0.1589 |
| September 30, 2019 | -0.1584 |
| June 30, 2019 | -0.1692 |
| March 31, 2019 | -0.2201 |
| December 31, 2018 | -0.219 |
| September 30, 2018 | -0.2984 |
| June 30, 2018 | -0.35 |
| March 31, 2018 | -0.3482 |
| December 31, 2017 | -0.31 |
| September 30, 2017 | -0.30 |
| June 30, 2017 | -0.29 |
| March 31, 2017 | -0.2985 |
| December 31, 2016 | -0.29 |
| September 30, 2016 | -0.39 |
| June 30, 2016 | -0.41 |
| March 31, 2016 | -0.38 |
| December 31, 2015 | -0.9455 |
| September 30, 2015 | -0.55 |
| June 30, 2015 | -2.380 |
| March 31, 2015 | -0.0578 |
| December 31, 2014 | -0.09 |
| March 31, 2014 | -0.0144 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -0.932 |
| Sarepta Therapeutics, Inc. | 2.878 |
| Cogent Biosciences, Inc. | -0.60 |
| Revolution Medicines, Inc. | -2.291 |
| Erasca, Inc. | -0.6028 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -632.80M |
| Revenue (Quarterly) | 44.21M |
| Total Expenses (Quarterly) | 676.99M |
| Enterprise Value | 8.547B |
| Gross Profit Margin (Quarterly) | 89.55% |
| Profit Margin (Quarterly) | -1.43K% |
| Earnings Yield | -11.46% |
| Normalized Earnings Yield | -7.095 |